ADMA Biologics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023, Fiscal Year 2024-2025
January 08, 2024 at 07:00 am EST
Share
ADMA Biologics, Inc. provided earnings guidance for the fourth quarter and full year ended December 31, 2023, fiscal year 2024-2025. For the quarter, the company estimates that its total revenue will be between $72 million and $74 million.
For the year ended December 31, 2023, the company expects total revenue between $256 million and $258 million, respectively.
For the year 2024-2025, the company expects Total Revenue expected to be in the range of $320 Million to $370 Million, respectively, increased from $290 Million and $335 Million previously and Net Income expected to exceed $60 Million to $110 Million, respectively, increased from $55 Million and $100 Million previously.
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
ADMA BIOLOGICS, INC. 
